Verrica Pharmaceuticals Inc is a therapeutics company developing and commercializing medications for the treatment of dermatologic diseases, including skin cancers... Show more
a manufacturer of pharmaceutical products
Industry Biotechnology
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| VFMO | 231.25 | 2.26 | +0.99% |
| Vanguard U.S. Momentum Factor ETF (VFMO) | |||
| TDAQ | 27.64 | 0.24 | +0.88% |
| TappAlpha Innovation 100 Growth & Daily Income ETF (TDAQ) | |||
| KEAT | 32.55 | 0.10 | +0.29% |
| Keating Active ETF (KEAT) | |||
| TMED | 33.22 | -0.12 | -0.36% |
| T. Rowe Price Health Care ETF (TMED) | |||
| SPOG | 6.16 | -0.55 | -8.22% |
| Leverage Shares 2X Long SPOT Daily ETF (SPOG) | |||
A.I.dvisor indicates that over the last year, VRCA has been loosely correlated with SVRA. These tickers have moved in lockstep 37% of the time. This A.I.-generated data suggests there is some statistical probability that if VRCA jumps, then SVRA could also see price increases.
| Ticker / NAME | Correlation To VRCA | 1D Price Change % | ||
|---|---|---|---|---|
| VRCA | 100% | -2.99% | ||
| SVRA - VRCA | 37% Loosely correlated | -4.66% | ||
| KTTA - VRCA | 35% Loosely correlated | -2.68% | ||
| RYTM - VRCA | 34% Loosely correlated | -0.62% | ||
| PHVS - VRCA | 32% Poorly correlated | +0.58% | ||
| SANA - VRCA | 32% Poorly correlated | N/A | ||
More | ||||
VRCA saw its Momentum Indicator move below the 0 level on October 01, 2026. This is an indication that the stock could be shifting in to a new downward move. Traders may want to consider selling the stock or exploring put options. Tickeron's A.I.dvisor looked at 90 similar instances where the indicator turned negative. In 82 of the 90 cases, the stock moved further down in the following days. The odds of a decline are at 90%.
VRCA moved below its 50-day moving average on August 31, 2026 date and that indicates a change from an upward trend to a downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where VRCA declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
VRCA broke above its upper Bollinger Band on August 28, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for VRCA entered a downward trend on October 02, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 60 of 67 cases where VRCA's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 90%.
The Moving Average Convergence Divergence (MACD) for VRCA just turned positive on September 30, 2026. Looking at past instances where VRCA's MACD turned positive, the stock continued to rise in 40 of 44 cases over the following month. The odds of a continued upward trend are 90%.
Following a +5.50% 3-day Advance, the price is estimated to grow further. Considering data from situations where VRCA advanced for three days, in 229 of 264 cases, the price rose further within the following month. The odds of a continued upward trend are 87%.
The Tickeron Valuation Rating of 62 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (18.349) is normal, around the industry mean (26.780). P/E Ratio (0.000) is within average values for comparable stocks, (43.395). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (0.000) among similar stocks. P/S Ratio (2.496) is also within normal values, averaging (438.009).
The Tickeron Price Growth Rating for this company is 80 (best 1 - 100 worst), indicating slightly worse than average price growth. VRCA’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 100 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. VRCA’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.